The Best Scientific References on Testosterone Replacement Therapy

REFERENCES

1. 1.↵
    

   1. Feldman HA, 
   2. Longcope C, 
   3. Derby CA, 
   4. et al.

    Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87:589–598.

   Abstract/FREE Full Text
2. 2.↵
    

   1. Araujo AB, 
   2. O’Donnell AB, 
   3. Brambilla DJ, 
   4. et al.

    Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89:5920–5926.

    

   Abstract/FREE Full Text
3. 3.↵
    

   1. Travison TG, 
   2. Shackelton R, 
   3. Araujo AB, 
   4. et al.

    The natural history of symptomatic androgen deficiency in men: onset, progression, and spontaneous remission. J Am Geriatr Soc2008; 56:831–839.

    

   CrossRefMedlineWeb of Science
4. 4.↵
    

   1. Tajar A, 
   2. Forti G, 
   3. O’Neill TW, 
   4. et al., 
   5. EMAS Group

   .Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 2010; 95:1810–1818.

   Abstract/FREE Full Text
5. 5.↵
    

   1. Hammes A, 
   2. Andreassen TK, 
   3. Spoelgen R, 
   4. et al.

    Role of endocytosis in cellular uptake of sex steroids. Cell 2005;122:751–762.

    

   CrossRefMedlineWeb of Science
6. 6.↵
    

   1. Rosner W, 
   2. Hryb DJ, 
   3. Kahn SM, 
   4. Nakhla AM, 
   5. Romas NA

   .Interactions of sex hormone-binding globulin with target cells.Mol Cell Endocrinol 2010; 316:79–85.

    

   CrossRefMedline
7. 7.↵
    

   1. Bhasin S, 
   2. Cunningham GR, 
   3. Hayes FJ, 
   4. et al., 
   5. Task Force, Endocrine Society

   . Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:2536–2559.

   Abstract/FREE Full Text
8. 8.↵
    

   1. Wang C, 
   2. Nieschlag E, 
   3. Swerdloff R, 
   4. et al., 
   5. International Society of Andrology (ISA), 
   6. International Society for the Study of Aging Male (ISSAM), 
   7. European Association of Urology (EAU),
   8. European Academy of Andrology (EAA), 
   9. American Society of Andrology (ASA)

   . Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl 2009; 30:1–9.

    

   FREE Full Text
9. 9.↵
    

   1. Morley JE, 
   2. Patrick P, 
   3. Perry HM 3rd.

   . Evaluation of assays available to measure free testosterone. Metabolism 2002;51:554–559.

    

   CrossRefMedlineWeb of Science
10. 10.↵
     

    1. Vesper HW, 
    2. Bhasin S, 
    3. Wang C, 
    4. et al.

     Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods.Steroids 2009; 74:498–503.

     

    CrossRefMedlineWeb of Science
11. 11.↵
     

    1. Ly LP, 
    2. Sartorius G, 
    3. Hull L, 
    4. et al.

     Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf) 2010;73:382–388.

     

    CrossRefMedline
12. 12.↵
     

    1. Melmed S, 
    2. Casanueva FF, 
    3. Hoffman AR, 
    4. et al.,
    5. Endocrine Society

    . Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273–288.

    Abstract/FREE Full Text
13. 13.↵
     

    1. Wu FC, 
    2. Tajar A, 
    3. Beynon JM, 
    4. et al., 
    5. EMAS Group

    .Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363:123–135.

     

    CrossRefMedline
14. 14.↵
     

    1. Kelleher S, 
    2. Conway AJ, 
    3. Handelsman DJ

    . Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 2004; 89:3813–3817.

    Abstract/FREE Full Text
15. 15.↵
     

    1. Joshi D, 
    2. van Schoor NM, 
    3. de Ronde W, 
    4. et al.

     Low free testosterone levels are associated with prevalence and incidence of depressive symptoms in older men. Clin Endocrinol (Oxf) 2010; 72:232–240.

     

    CrossRefMedline
16. 16.↵
     

    1. Shores MM, 
    2. Kivlahan DR, 
    3. Sadak TI, 
    4. Li EJ,
    5. Matsumoto AM

    . A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry 2009; 70:1009–1016.

     

    CrossRefMedlineWeb of Science
17. 17.↵
     

    1. Khera M, 
    2. Bhattacharya RK, 
    3. Blick G, 
    4. Kushner H,
    5. Nguyen D, 
    6. Miner MM

    . The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). Aging Male 2012;15:14–21.

     

    CrossRefMedline
18. 18.↵
     

    1. Jain P, 
    2. Rademaker AW, 
    3. McVary KT

    . Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 2000; 164:371–375.

     

    CrossRefMedlineWeb of Science
19. 19.↵
     

    1. Mulhall JP, 
    2. Valenzuela R, 
    3. Aviv N, 
    4. Parker M

    . Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction. Urology 2004;63:348–352.

     

    CrossRefMedline
20. 20.↵
     

    1. Morley JE, 
    2. Charlton E, 
    3. Patrick P, 
    4. et al.

     Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49:1239–1242.

     

    CrossRefMedlineWeb of Science
21. 21.↵
     

    1. Moore C, 
    2. Huebler D, 
    3. Zimmermann T, 
    4. Heinemann LA,
    5. Saad F, 
    6. Thai DM

    . The Aging Males’ Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004; 46:80–87.

     

    CrossRefMedlineWeb of Science
22. 22.↵
     

    1. Chueh KS, 
    2. Huang SP, 
    3. Lee YC, 
    4. et al.

     The Comparison of the Aging Male Symptoms (AMS) Scale and Androgen Deficiency in the Aging Male (ADAM) Questionnaire to Detect Androgen Deficiency in Middle-Aged Men. J Androl 2012 [Epub ahead of print]

     

    Search Google Scholar
23. 23.↵
     

    1. Mulligan T, 
    2. Frick MF, 
    3. Zuraw QC, 
    4. Stemhagen A,
    5. McWhirter C

    . Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60:762–769.

    CrossRefMedlineWeb of Science
24. 24.↵
     

    1. Dhindsa S, 
    2. Miller MG, 
    3. McWhirter CL, 
    4. et al.

    Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010; 33:1186–1192.

    Abstract/FREE Full Text
25. 25.
     

    1. Krasnoff JB, 
    2. Basaria S, 
    3. Pencina MJ, 
    4. et al.

     Free testosterone levels are associated with mobility limitation and physical performance in community-dwelling men: the Framingham Offspring Study. J Clin Endocrinol Metab 2010;95:2790–2799.

     

    Abstract/FREE Full Text
26. 26.↵
     

    1. Carrero JJ, 
    2. Qureshi AR, 
    3. Nakashima A, 
    4. et al.

     Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant 2011;26:184–190.

     

    Abstract/FREE Full Text
27. 27.↵
     

    1. Grossmann M, 
    2. Thomas MC, 
    3. Panagiotopoulos S, 
    4. et al.

    Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab2008; 93:1834–1840.

     

    Abstract/FREE Full Text
28. 28.↵
     

    1. Brand JS, 
    2. van der Tweel I, 
    3. Grobbee DE,
    4. Emmelot-Vonk MH, 
    5. van der Schouw YT

    . Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies.Int J Epidemiol 2011; 40:189–207.

     

    Abstract/FREE Full Text
29. 29.↵
     

    1. Ding EL, 
    2. Song Y, 
    3. Malik VS, 
    4. Liu S

    . Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006;295:1288–1299.

     

    CrossRefMedlineWeb of Science
30. 30.↵
     

    1. Niskanen L, 
    2. Laaksonen DE, 
    3. Punnonen K, 
    4. Mustajoki P,
    5. Kaukua J, 
    6. Rissanen A

    . Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab 2004; 6:208–215.

     

    CrossRefMedlineWeb of Science
31. 31.↵
     

    1. Shores MM, 
    2. Matsumoto AM, 
    3. Sloan KL, 
    4. Kivlahan DR

    .Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166:1660–1665.

     

    CrossRefMedlineWeb of Science
32. 32.↵
     

    1. Carrero JJ, 
    2. Qureshi AR, 
    3. Parini P, 
    4. et al.

     Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009; 20:613–620.

    Abstract/FREE Full Text
33. 33.↵
     

    1. Haring R, 
    2. Völzke H, 
    3. Steveling A, 
    4. et al.

     Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur Heart J 2010; 31:1494–1501.

     

    Abstract/FREE Full Text
34. 34.↵
     

    1. Araujo AB, 
    2. Dixon JM, 
    3. Suarez EA, 
    4. Murad MH, 
    5. Guey LT,
    6. Wittert GA

    . Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96:3007–3019.

     

    Abstract/FREE Full Text
35. 35.↵
     

    1. Rhoden EL, 
    2. Morgentaler A

    . Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350:482–492.

     

    CrossRefMedlineWeb of Science
36. 36.↵
     

    1. Isbarn H, 
    2. Pinthus JH, 
    3. Marks LS, 
    4. et al.

     Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009;56:48–56.

     

    CrossRefMedline
37. 37.↵
     

    1. Traish AM, 
    2. Miner MM, 
    3. Morgentaler A, 
    4. Zitzmann M

    .Testosterone deficiency. Am J Med 2011; 124:578–587.

    CrossRefMedline
38. 38.↵
     

    1. Cavender RK, 
    2. Fairall M

    . Subcutaneous testosterone pellet implant (Testopel) therapy for men with testosterone deficiency syndrome: a single-site retrospective safety analysis.J Sex Med 2009; 6:3177–3192.

     

    CrossRefMedline
39. 39.↵
     

    1. Gerstenbluth RE, 
    2. Maniam PN, 
    3. Corty EW, 
    4. Seftel AD

    .Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl 2002; 23:922–926.

    Abstract/FREE Full Text
40. 40.↵
     

    1. Corona G, 
    2. Monami M, 
    3. Rastrelli G, 
    4. et al.

     Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med2011; 8:272–283.

     

    CrossRefMedline
41. 41.↵
     

    1. Corona G, 
    2. Rastrelli G, 
    3. Monami M, 
    4. et al.

     Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011; 165:687–701.

    Abstract/FREE Full Text
42. 42.↵
     

    1. Kapoor D, 
    2. Goodwin E, 
    3. Channer KS, 
    4. Jones TH

    .Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol2006; 154:899–906.

     

    Abstract/FREE Full Text
43. 43.↵
     

    1. Aversa A, 
    2. Bruzziches R, 
    3. Francomano D, 
    4. et al.

     Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010; 7:3495–3503.

     

    CrossRefMedline
44. 44.↵
     

    1. Rhoden EL, 
    2. Morgentaler A

    . Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice. J Sex Med 2010;7:277–283.

     

    Medline
45. 45.↵
     

    1. Khera M, 
    2. Bhattacharya RK, 
    3. Blick G, 
    4. Kushner H,
    5. Nguyen D, 
    6. Miner MM

    . Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med 2011; 8:3204–3213.

     

    CrossRefMedline
46. 46.↵
     

    1. Buvat J, 
    2. Montorsi F, 
    3. Maggi M, 
    4. et al.

     Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med 2011; 8:284–293.

     

    CrossRefMedline
47. 47.↵
     

    1. Basaria S, 
    2. Coviello AD, 
    3. Travison TG, 
    4. et al.

     Adverse events associated with testosterone administration. N Engl J Med 2010; 363:109–122.

     

    CrossRefMedline
48. 48.↵
     

    1. Dobs AS, 
    2. Meikle AW, 
    3. Arver S, 
    4. Sanders SW,
    5. Caramelli KE, 
    6. Mazer NA

    . Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab1999; 84:3469–3478.

     

    Abstract/FREE Full Text
49. 49.↵
     

    1. Wang C, 
    2. Swerdloff RS, 
    3. Iranmanesh A, 
    4. et al.,
    5. Testosterone Gel Study Group

    . Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2839–2853.

     

    Abstract/FREE Full Text
50. 50.↵
     

    1. Hanafy HM

    . Testosterone therapy and obstructive sleep apnea: is there a real connection? J Sex Med 2007;4:1241–1246.

     

    CrossRefMedline
51. 51.↵
     

    1. Coward RM, 
    2. Simhan J, 
    3. Carson CC 3rd.

    . Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int2009; 103:1179–1183.

     

    CrossRefMedline
52. 52.↵
     

    1. Siegel R, 
    2. Naishadham D, 
    3. Jemal A

    . Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10–29.

     

    CrossRefMedlineWeb of Science
53. 53.↵
     

    1. Morgentaler A, 
    2. Traish AM

    . Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310–320.

     

    CrossRefMedline
54. 54.↵
     

    1. Page ST, 
    2. Lin DW, 
    3. Mostaghel EA, 
    4. et al.

    Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.J Clin Endocrinol Metab 2011; 96:430–437.

    Abstract/FREE Full Text
55. 55.↵
     

    1. Botto H, 
    2. Neuzillet Y, 
    3. Lebret T, 
    4. Camparo P, 
    5. Molinie V,
    6. Raynaud JP

    . High incidence of predominant Gleason pattern 4 localized prostate cancer is associated with low serum testosterone. J Urol 2011; 186:1400–1405.

     

    CrossRefMedline
56. 56.↵
     

    1. Salonia A, 
    2. Gallina A, 
    3. Briganti A, 
    4. et al.

     Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. Cancer2011; 117:3953–3962.

     

    CrossRefMedlineWeb of Science
57. 57.↵
     

    1. Sarosdy MF

    . Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007; 109:536–541.

     

    CrossRefMedline
58. 58.↵
     

    1. Khera M

    . Androgens and erectile function: a case for early androgen use in postprostatectomy hypogonadal men. J Sex Med 2009; 6:(suppl 3):234–238.

     

    CrossRefMedlineWeb of Science
59. 59.↵
     

    1. Szmulewitz R, 
    2. Mohile S, 
    3. Posadas E, 
    4. et al.

     A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009; 56:97–103.

     

    CrossRefMedline
60. 60.↵
     

    1. Morgentaler A, 
    2. Lipshultz LI, 
    3. Bennett R, 
    4. Sweeney M,
    5. Avila D Jr., 
    6. Khera M

    . Testosterone therapy in men with untreated prostate cancer. J Urol 2011; 185:1256–1260.

    CrossRefMedline